Trial Profile
A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolisation (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jul 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 15 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jan 2014 Planned End Date changed from 1 Sep 2013 to 1 Mar 2016 as per ClinicalTrials.gov.